PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in the following investor conferences in September.
Wells Fargo Healthcare Conference
| Date / Time: | September 3rd, at 2:15 PM ET |
| Format: | Fireside Chat |
| Location: | Boston, MA |
Cantor Fitzgerald Global Healthcare Conference
| Date / Time: | September 4th, at 3:55 PM ET |
| Format: | Fireside Chat |
| Location: | New York, NY |
H.C. Wainwright 27th Annual Global Healthcare Conference
| Date / Time: | September 8th, at 9:00 AM ET |
| Format: | Fireside Chat |
| Location: | New York, NY |
The conference webcasts will be available through the Events section of the Company’s Investor Relations website. Replays will be available for approximately 90 days following the event.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is the first and only FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
609-460-3583 ext. 1083
| Last Trade: | US$18.50 |
| Daily Change: | -0.94 -4.84 |
| Daily Volume: | 1,385,341 |
| Market Cap: | US$855.810M |
August 07, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
